Novel inhibitors of the αvβ3 integrin—lead identification strategy
Authors:
- Eleanor HenshawEHEleanor Henshaw
- Philip A. MacFaulPMPhilip A. MacFaul
- Andrew D. MorleyAMAndrew D. Morley
- Peter NewhamPNPeter Newham
- Keith OldhamKOKeith Oldham
- Ken PageKPKen Page
- Neil RankineNRNeil Rankine
- Paul SharpePSPaul Sharpe
- Attilla TingATAttilla Ting
- Christine M. WoodCWChristine M. Wood
- 1 August 2009
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (16) , 4832-4835
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Involvement of αvβ3 integrins in osteoclast functionJournal of Bone and Mineral Metabolism, 2007
- Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 AntagonismAnti-Cancer Agents in Medicinal Chemistry, 2006
- Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/αIIbβ3 dual antagonistic activityBioorganic & Medicinal Chemistry, 2006
- Vitronectin Receptor -αVβ3 Integrin- Antagonists: Chemical and Structural Requirements for Activity and SelectivityMini-Reviews in Medicinal Chemistry, 2002
- Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseasesAnnals of the Rheumatic Diseases, 2002
- IntegrinsCell, 2002
- Ligands to the integrin receptor αvβ3Expert Opinion on Therapeutic Patents, 2002
- Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp LigandScience, 2002
- An imidazoline pseudodipeptide suitable for solid phase peptide synthesisJournal of Peptide Science, 2000
- Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 AntagonistJournal of Medicinal Chemistry, 2000